Serplulimab
- Generic Name
- Serplulimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2231029-82-4
- Unique Ingredient Identifier
- S3GQZ2K36V
- Indication
用于经过标准治疗失败的、不可切除或转移性高度微卫星不稳定型（MSI-H）成人晚期实体瘤患者。
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 36
- Registration Number
- NCT05957510
- Locations
- 🇨🇳
Guangdong Provincial Perople's Hospital, Guangzhou, Guangdong, China
A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-isolated Hepatic Metastatic Colorectal Cancer: a Single-center, Phase 2 Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Junjie Peng
- Target Recruit Count
- 50
- Registration Number
- NCT05954429
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT05918419
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 118
- Registration Number
- NCT05883670
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Yu jiren
- Target Recruit Count
- 314
- Registration Number
- NCT05872685
- Locations
- 🇨🇳
Lishui Central Hospital, Lishui, Zhejiang, China
🇨🇳The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Taizhou Hospital, Taizhou, Zhejiang, China
A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Shanghai Henlius Biotech
- Target Recruit Count
- 132
- Registration Number
- NCT05787613
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT05769725
- Locations
- 🇨🇳
Zhang Zizhen, Shanghai, China
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 100
- Registration Number
- NCT05766800
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 61
- Registration Number
- NCT05765825
- Locations
- 🇨🇳
GuiZhou Provincial People's Hospital, Guiyang, China
🇨🇳Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
🇨🇳Chongqing University cancer hospital, Chongqing, Chongqing, China
Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
- Conditions
- Interventions
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2023-02-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT05732493
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.